2008
NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment
Knopp EA, Cowper SE. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment. Seminars In Dialysis 2008, 21: 123-128. PMID: 18226008, DOI: 10.1111/j.1525-139x.2007.00399.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsContrast MediaEarly DiagnosisFibrosisGadoliniumHumansKidney Failure, ChronicPhotopheresisRisk FactorsSkin DiseasesConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsEarly recognitionSystemic fibrosisAcute kidney diseaseSignificant risk factorsInvolved extremityRenal dysfunctionRenal insufficiencyExtracorporeal photopheresisRenal functionMedical therapyMuscle weaknessKidney diseaseRisk factorsDistressing diseaseEarly treatmentPhysical therapyEffective treatmentEarly symptomsEarly signsPatientsBeneficial effectsFibrosisTherapy
2007
Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders
Cowper SE, Kuo PH, Bucala R. Nephrogenic systemic fibrosis and gadolinium exposure: Association and lessons for idiopathic fibrosing disorders. Arthritis & Rheumatism 2007, 56: 3173-3175. PMID: 17907160, DOI: 10.1002/art.22926.Commentaries, Editorials and LettersGadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis
High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. Journal Of The American Academy Of Dermatology 2007, 56: 710-712. PMID: 17289213, DOI: 10.1016/j.jaad.2007.01.022.Peer-Reviewed Original ResearchNephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure
Deo A, Fogel M, Cowper SE. Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure. Clinical Journal Of The American Society Of Nephrology 2007, 2: 264-267. PMID: 17699423, DOI: 10.2215/cjn.03921106.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsGadolinium exposureIncidence of NSFSevere renal failurePopulation of patientsMajor risk factorOccurrence of NSFDevastating complicationESRD populationRenal failureSignificant morbidityRadiologic studiesRisk factorsSystemic fibrosisPopulation studiesESRDPatientsDisease developmentRecent reportsExposureContrast agentsRiskMorbidityComplicationsGadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1. Radiology 2007, 242: 647-9. PMID: 17213364, DOI: 10.1148/radiol.2423061640.Commentaries, Editorials and Letters
2006
Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)
Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Current Opinion In Rheumatology 2006, 18: 614-617. PMID: 17053507, DOI: 10.1097/01.bor.0000245725.94887.8d.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisSystemic fibrosisNephrogenic fibrosing dermopathyRenal insufficiencyClinical awarenessSystemic diseaseClinical spectrumTreatment optionsFibrogenic factorsEffective therapyFatal disorderEnigmatic disorderClinical reportsCardinal featuresFibrosisSpecific causesDisordersPathogenesisFibrocytesFuture studiesCauseRheumatologistsPatientsEtiopathogenesisRegistryEditorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients
DeHoratius DM, Cowper SE. Editorials: Nephrogenic Systemic Fibrosis: An Emerging Threat Among Renal Patients. Seminars In Dialysis 2006, 19: 191-194. PMID: 16689966, DOI: 10.1111/j.1525-139x.2006.00152.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsComorbidityDiagnosis, DifferentialFibrosisHumansKidney Failure, ChronicSkin DiseasesThrombophiliaThrombosisConceptsNephrogenic systemic fibrosisSystemic fibrosisCases of NSFNephrogenic fibrosing dermopathyScleroderma-like diseaseRenal insufficiencyRenal patientsNSF patientsNephrology professionalsPatientsNephrology literatureSoft tissueTissue remodelingWound repairFibrosisSkinSpecific cellsComorbiditiesDermopathyInsufficiencySymptomsDiseaseNephrogenic systemic fibrosis: An update
Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: An update. Current Rheumatology Reports 2006, 8: 151-157. PMID: 16569375, DOI: 10.1007/s11926-006-0056-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2005
Case 35-2004: nephrogenic fibrosing dermopathy.
Cowper S, Bucala R, LeBoit P. Case 35-2004: nephrogenic fibrosing dermopathy. New England Journal Of Medicine 2005, 352: 1723-4; author reply 1723-4. PMID: 15846862.Peer-Reviewed Original Research
2003
Nephrogenic fibrosing dermopathy: the first 6 years
Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Current Opinion In Rheumatology 2003, 15: 785-790. PMID: 14569211, DOI: 10.1097/00002281-200311000-00017.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic fibrosing dermopathyRecent case reportsCase reportCutaneous fibrosing disorderYellow scleral plaquesDistinct clinical patternsDual immunohistochemical stainingAntiphospholipid antibodiesRenal insufficiencyClinical patternDual immunolabelingFibrosing disorderSystemic disordersClinical spectrumScleral plaquesDisease onsetEpidemiologic dataSpindle cellsImmunohistochemical stainingDisease triggersSkin conditionsDisease pathogenesisNormal skinRegistry projectDiagnostic tests